Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, 80-214, Poland.
Department of Algorithms and System Modeling, Gdansk University of Technology, Gdańsk, Poland.
Pharmacol Rep. 2024 Dec;76(6):1325-1332. doi: 10.1007/s43440-024-00641-1. Epub 2024 Aug 29.
This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration.
This is a post-hoc analysis of a naturalistic observational study, which enrolled 28 inpatients with treatment-resistant major depressive disorder and analyzed self-reported sleep changes (items 1-4; 'insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') in Inventory of Depressive Symptomatology 30-item (IDS SR-30) in responders and non-responders stratified per Montgomery-Åsberg Depression Rating Scale (MADRS) during short-term ketamine treatment.
Responders, as well as non-responders, did not experience significant changes in IDS SR-30 sleep items ('insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') (p's > 0.05) at 7-day follow-up after eight intravenous ketamine infusions as compared to baseline.
Neither responders, nor non-responders reported any significant alterations in sleep patterns during ketamine infusions. These findings are not in line with current literature, as so far modest improvements in sleep during ketamine treatment have been reported. Results should be interpreted with caution, primarily due to the small sample size.
本研究考察了静脉注射氯胺酮治疗后,治疗抵抗性抑郁症(TRD)住院患者的自我报告睡眠改变。
这是一项自然观察研究的事后分析,共纳入 28 名治疗抵抗性重度抑郁症住院患者,根据蒙哥马利-Åsberg 抑郁评定量表(MADRS),分析了短期氯胺酮治疗期间的应答者和无应答者自我报告的睡眠变化(项目 1-4;“失眠”、“夜间不安”、“早醒”、“嗜睡”),并在 Inventory of Depressive Symptomatology 30-item(IDS SR-30)中进行了分析。
与基线相比,在接受 8 次静脉注射氯胺酮后 7 天的随访中,应答者和无应答者在 IDS SR-30 睡眠项目(“失眠”、“夜间不安”、“早醒”、“嗜睡”)上均未出现显著变化(p>0.05)。
无论是应答者还是无应答者,在氯胺酮输注期间均未报告睡眠模式有任何显著改变。这些发现与目前的文献不一致,因为迄今为止,氯胺酮治疗期间睡眠有适度改善的报道。结果应谨慎解释,主要是由于样本量小。